首页> 美国卫生研究院文献>Springer Open Choice >Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets

【2h】

Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets

机译：联合疗法应成为实现LDL-胆固醇目标的新护理标准的原因

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Cardiovascular risk categories, recommended LDL-C targets, evidence class and level, and treatment recommendations addressed to increase target attainment

机译：心血管风险类别，推荐的LDL-C目标，证据分类和水平以及为提高目标达成率而提出的治疗建议

著录项

期刊名称 Springer Open Choice
作者
Lluís Masana; Daiana Ibarretxe; Núria Plana;
展开▼
作者单位

展开▼
年(卷),期 -1(22),8
年度 -1
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类外科学;
关键词
Lipid-lowering combination therapy; Statins; Ezetimibe; PCSK9 inhibitors; Cardiovascular prevention;

机译：降脂联合疗法;他汀类药物;依泽替米贝;PCSK9抑制剂;心血管预防;

相似文献

外文文献
中文文献
专利

1. Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations [J] . Limin Li, Xiaoqian Zhang, Hongjuan Yu, OncoTargets and therapy . 2018,第2期

机译：低剂量次甲基化剂地西他滨联合阿克拉霉素和阿糖胞苷在难治性/复发性细胞遗传学和突变风险低的急性/复发性急性髓细胞白血病患者中取得比标准FLAG化疗更好的结果
2. Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and nonsquamous subtypes of non-small cell lung cancer [J] . Masaru Katoh Journal of Thoracic Disease . 2018,第9期

机译：组合免疫肿瘤学治疗PEMBROLIZUMAB，靶向免疫浸润的抗PD-1单克隆抗体，以及用于非小细胞肺癌的鳞状和非谐起亚型的患者的标准化学疗法
3. Erratum to: Five Reasons Why Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Must be Regarded as the New Standard of Care for Diffuse Malignant Peritoneal Mesothelioma [J] . Annals of Surgical Oncology . 2011,第s3期

机译：勘误：为何必须采取细胞减缩术加高温腹膜内化疗作为弥漫性恶性腹膜间皮瘤治疗新标准的五个原因
4. Achieving cancer cell death with PI3K/mTOR-targeted therapies [C] . Sung Su Yea, David A. Fruman Inositol Phospholipid Signaling in Physiology and Disease (Conference) . 2013

机译：用PI3K / MTOR靶向疗法实现癌症细胞死亡
5. Oncolytic Vaccinia Virus for the Treatment of Peritoneal Carcinomatosis: Combination with Chemotherapy or Targeted Radiotherapy [D] . Ottolino-Perry, Kathryn. 2015

机译：用于治疗腹膜癌症的植物疫苗病毒：与化疗或靶向放射的组合
6. Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations [O] . Limin Li, Xiaoqian Zhang, Hongjuan Yu, 2018

机译：低剂量次甲基化剂地西他滨联合阿克拉霉素和阿糖胞苷在难治性/复发性细胞遗传学和突变风险低的急性/复发性急性髓细胞白血病患者中取得比标准FLAG化疗更好的结果
7. Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations [O] . Limin Li, Xiaoqian Zhang, Hongjuan Yu, 2018

机译：低剂量的低甲基化剂与海红霉素和红霉素组合的二亚滨达到了难治性/复发的急性髓性白血病患者的标准标志化疗的更好的结果，患有贫困的细胞遗传学和突变

Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets

摘要

著录项

相似文献

相关主题

期刊订阅